RBC keeps GBp 1,975 target for GSK stock

Published on 10/19/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue is forecast at GBP 8.82 billion for October 28. GSK stock costs EUR 22.11 on October 19, 2026, 0.18 percent above Xetra close.

Analyst target and catalysts

RBC Capital Markets maintained a GBp 1,975 target on October 13, 2026.
RBC forecasts third-quarter revenue of GBP 8.82 billion versus GBP 8.89 billion consensus for October 28, 2026.
GSK stock trades at EUR 22.11 at 10:07 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.18 percent above the Xetra close of October 16, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock (ISIN GB00BN7SWP63) was trading at EUR 22.11 at Lang & Schwarz on October 19, 2026 at 10:07 a.m. CEST, 0.18 percent above the Xetra close of October 16, 2026 at EUR 22.07. The near-term test is the drugmaker's third-quarter update and the outlook for vaccines, HIV medicines and respiratory products.

RBC Capital Markets maintained its Sector Perform rating and GBp 1,975 price target on October 13, 2026, as Yahoo Finance reported. The broker expects vaccine pressure to offset strength in HIV treatments and Nucala.

What could shape the quarter?

RBC forecasts third-quarter revenue of GBP 8.82 billion, below the GBP 8.89 billion consensus estimate, while core earnings per share of GBp 50.80 are expected to match consensus, according to Yahoo Finance. Its forecast puts Shingrix revenue at GBP 800.00 million and Nucala revenue at GBP 623.00 million.

Three dated steps for GSK

On July 15, 2026, GSK completed its acquisition of Nuvalent, a transaction valued at USD 10.60 billion. On July 28, 2026, second-quarter sales reached GBP 8.41 billion, up 5.00 percent, while specialty-medicine sales rose 14.00 percent. On October 13, 2026, RBC kept its GBp 1,975 target. These company developments and figures are summarized by Tickerstat.

Upcoming dates carry the next signals

Two near-term catalysts precede the results: a United States regulatory decision on bepirovirsen is expected on October 26, 2026, followed by an oncology data update on October 27, 2026, according to Yahoo Finance. GSK is scheduled to present its third-quarter results on October 28, 2026, with consensus revenue of USD 11.82 billion and consensus earnings per share of USD 1.34, according to finanzen.ch.

GSK stock stays near its Xetra close

The small euro move leaves the analyst target and the October results as the clearest dated reference points for the next assessment of GSK stock.

GSK stock was trading at EUR 22.11 at Lang & Schwarz on October 19, 2026 at 10:07 a.m. CEST, 0.18 percent above the Xetra close of October 16, 2026 at EUR 22.07. The further course of trading is shown by the continuously updated real-time quote of GSK stock.